Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709683 | 0.85 | TSHR (0.62) | ALDH1A1HTTTSHRKDM4EMEN1 | |
| SCHEMBL10869745 | 0.82 | ALDH1A1 (0.68) | ALDH1A1CYP3A4MAPK1HTTCNR2 | |
| SCHEMBL1468205 | 0.82 | CYP2D6 (0.50) | ALDH1A1HTTTSHRMEN1KMT2A | |
| SCHEMBL3166437 | 0.82 | HTT (0.47) | ALDH1A1HTTTSHRMEN1KMT2A | |
| SCHEMBL5879758 | 0.82 | CYP2C9 (0.55) | ALDH1A1MAPK1HTTTSHRKDM4E | |
| SCHEMBL16494906 | 0.81 | NFE2L2 (0.49) | ALDH1A1HTTTSHRCNR2MEN1 | |
| SCHEMBL1465612 | 0.79 | KIF18A (0.51) | ALDH1A1CYP3A4MAPK1HTTTSHR | |
| SCHEMBL1466470 | 0.78 | TDP1 (0.50) | ALDH1A1CNR2MEN1KMT2AHSD11B1 | |
| SCHEMBL16220186 | 0.78 | KMT2A (0.50) | ALDH1A1HTTTSHRMEN1KMT2A | |
| SCHEMBL16494957 | 0.78 | PKM (0.56) | ALDH1A1HTTPKMPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110117264-A | Phenyl sulfone derivative and its application on drug | 广东东阳光药业有限公司 | 2019-08-13 | — | — | CN | disclosed |
| EP-2526945-A1 | New CRTH2 Antagonists | Almirall, S.A. (ES) | 2012-11-28 | — | — | EP | disclosed |
| US-8268878-B2 | Compounds having CRTH2 antagonist activity | OXAGEN LIMITED (GB) | 2012-09-18 | — | — | US | disclosed |
| EP-2492268-A1 | Compounds having CRTH2 antagonist activity | Oxagen Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| EP-2046740-B1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | OXAGEN LTD (GB) | 2012-05-23 | — | — | EP | disclosed |
| US-20110268693-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-7999119-B2 | Compounds having CRTH2 antagonist activity | OXAGEN LIMITED (GB) | 2011-08-16 | — | — | US | disclosed |
| US-7994154-B2 | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | Ersai R&D Management Co., Ltd. (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100227835-A1 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-09-09 | — | — | US | disclosed |
| US-7737129-B2 | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-6184366-B1 | COMPOUND OF DEFINED STRUCTURE WHICH IS CHEMICAL INTERMEDIATE | EISAI CO., LTD (JP) | 2001-02-06 | — | — | US | disclosed |
| US-5952309-A | ADMINISTERING NOVEL ANALOGS OF LIPID A WHICH ACT AS ENDOTOXIN ANTAGONISTS | EISAI COMPANY, LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| US-5935938-A | TREATMENT OF SEPSIS | EISAI CO., LTD. (JP) | 1999-08-10 | — | — | US | disclosed |
| EP-0853627-A4 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA | EISAI CO LTD (JP) | 1998-10-07 | — | — | EP | disclosed |
| EP-0853627-A1 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA | Eisai Co., Ltd. (JP) | 1998-07-22 | — | — | EP | disclosed |
| US-5750664-A | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | EISAI CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5681824-A | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | EISAI CO., LTD. (JP) | 1997-10-28 | — | — | US | disclosed |
| WO-1997011708-A9 | METHOD FOR TREATING ALCOHOLIC LIVER DISEASE | — | 1997-05-15 | — | — | WO | disclosed |
| WO-1997011708-A1 | METHOD FOR TREATING ALCOHOLIC LIVER DISEASE | EISAI RESEARCH INSTITUTE (US) | 1997-04-03 | — | — | WO | disclosed |
| WO-1996039411-A1 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA | EISAI CO., LTD. (JP) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227835-A1 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA | LIPG, FUT6, UGCG | ALDH1A1 1479/4885CYP3A4 2918/4885MAPK1 3870/4885 |
| US-20110268693-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, HRH1, HRH4 | ALDH1A1 1293/4885CYP3A4 960/4885MAPK1 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.